Oramed Pharmaceuticals Inc (ORMP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Oramed Pharmaceuticals Inc (ORMP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013560
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イスラエル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Oramed Pharmaceuticals Inc (Oramed) engages in the research and development of novel pharmaceutical solutions, comprising an oral insulin capsule for the treatment of individuals with diabetes, and orally ingestible capsules or pills for delivery of other polypeptides. It developed a unique proprietary platform technology, Protein Oral Delivery (POD) to transform injectable treatments into oral therapies. The technology allows for the oral delivery of drugs currently administered only by injection. The company tested its technology through various animal and human studies on its two flagship products, ORMD-0801, an orally ingestible insulin capsule; and ORMD-0901, an oral GLP-1 analog (exenatide) capsule. Oramed is headquartered in Jerusalem, Israel.

Oramed Pharmaceuticals Inc (ORMP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Licensing Agreements 11
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 11
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 12
Hefei Tianhui Incubator of Technologies Enters into Licensing Agreement with Oramed Pharma 13
Equity Offering 14
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 14
Oramed Pharma Raises USD12 Million in Private Placement of Shares 15
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 16
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 18
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 19
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 21
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 22
Oramed Pharma Completes Private Placement Of Units US$5 Million 23
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 24
Oramed Pharma Completes Private Placement For US$3.36 Million 25
Acquisition 27
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
D.N.A Biomedical Completes Acquisition Of 47% JV Stake In Entera Bio From Oramed For US$1 Million 29
Oramed Pharmaceuticals Inc – Key Competitors 30
Oramed Pharmaceuticals Inc – Key Employees 31
Oramed Pharmaceuticals Inc – Locations And Subsidiaries 32
Head Office 32
Other Locations & Subsidiaries 32
Joint Venture 32
Recent Developments 33
Corporate Communications 33
Mar 21, 2017: Oramed Appoints Dr. Ronald Law as Chief Strategy Officer 33
Product News 34
06/21/2016: Oramed Announces $6.5 Million Milestone Payment from HTIT 34
05/02/2017: Oramed Receives Israel Regulatory Approval to Conduct Human Study for New Oral Leptin Capsule 35
Clinical Trials 36
Aug 02, 2016: Oramed Receives Additional $4 Million Milestone Payment From HTIT 36
Jul 28, 2016: Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo 37
May 18, 2016: Oramed Announces Positive Top-Line Results from Phase IIb Oral Insulin Study 38
Apr 05, 2016: Oramed Completes Phase IIb Oral Insulin Study 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Oramed Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Oramed Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Oramed to Enter into Licensing Agreement with Sinopharm and Hefei Life Science 11
Guangxi Wuzhou Pharma Enters into Licensing Agreement with Oramed Pharma 12
Hefei Tianhui Incubator of Technologies Enters into Licensing Agreement with Oramed Pharma 13
Oramed Pharma to Raise up to USD25 Million in Public Offering of Shares 14
Oramed Pharma Raises USD12 Million in Private Placement of Shares 15
Oramed Pharma Raises USD5.4 Million in Private Placement of Shares 16
Oramed Pharma to Raise USD5.4 Million in Private Placement of Shares 18
Oramed Pharma Completes Private Placement Of Shares For US$15.8 Million 19
Oramed Pharma Completes Private Placement Of Shares For US$4.6 Million 21
Oramed Pharma Withdraws Public Offering Of Common Stock For US$13 Million 22
Oramed Pharma Completes Private Placement Of Units US$5 Million 23
Oramed Pharma Completes Private Placement Of Units For US$3.6 Million 24
Oramed Pharma Completes Private Placement For US$3.36 Million 25
Sinopharm and Hefei Life Science to Acquire 10% Stake In Oramed Pharma 27
Guangxi Wuzhou Pharma Acquires Stake in Oramed Pharma for USD5 Million 28
D.N.A Biomedical Completes Acquisition Of 47% JV Stake In Entera Bio From Oramed For US$1 Million 29
Oramed Pharmaceuticals Inc, Key Competitors 30
Oramed Pharmaceuticals Inc, Key Employees 31
Oramed Pharmaceuticals Inc, Subsidiaries 32
Oramed Pharmaceuticals Inc, Joint Venture 32

★海外企業調査レポート[Oramed Pharmaceuticals Inc (ORMP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Hermes Europe GmbH:企業の戦略的SWOT分析
    Hermes Europe GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • University of Wisconsin Madison-製薬・医療分野:企業M&A・提携分析
    Summary University of Wisconsin Madison (UW-Madison), a subsidiary of University of Wisconsin System is an educational and research institution that provides undergraduate and postgraduate courses. The institution offers courses in various fields such as agricultural and life sciences, arts, busines …
  • Depuy Synthes Companies
    Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report Summary Depuy Synthes Companies - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Asuragen Inc:医療機器:M&Aディール及び事業提携情報
    Summary Asuragen Inc (Asuragen) is an oncology molecular diagnostic company that provides laboratory medicine solutions. The company offers products such as amplidex, quantidex, and custom reagents. It provides custom and companion diagnostic services, which include commercialization, product approv …
  • BASF SE (BAS)-製薬・医療分野:企業M&A・提携分析
    Summary BASF SE (BASF) is a chemical company, which carries out research and development (R&D), production, marketing and sales of chemicals, plastics, crop protection products, and performance products. Its product line comprises solvents, adhesives, surfactant, organic chemicals, fuel additives, e …
  • Cumberland Pharmaceuticals Inc (CPIX):製薬・医療:M&Aディール及び事業提携情報
    Summary Cumberland Pharmaceuticals Inc (Cumberland Pharma) is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products. Its primary target markets are hospital acute care, gastroenterology and cancer supportive care. The company offers branded presc …
  • Wynn Macau Ltd:戦略・SWOT・企業財務分析
    Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report Summary Wynn Macau Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Hologic, Inc.:企業の戦略・SWOT・財務情報
    Hologic, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hologic, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Pt Mandom Indonesia Tbk:企業の戦略・SWOT・財務情報
    Pt Mandom Indonesia Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Mandom Indonesia Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Advanced Digital Broadcast SA:企業の戦略的SWOT分析
    Advanced Digital Broadcast SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Medtronic PLC:企業のM&A・事業提携・投資動向
    Medtronic PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Medtronic PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Enerchem International Inc:企業の戦略的SWOT分析
    Enerchem International Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Mizuho Financial Group Inc:企業のM&A・事業提携・投資動向
    Mizuho Financial Group Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mizuho Financial Group Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • TE Connectivity Ltd (TEL):企業の財務・戦略的SWOT分析
    TE Connectivity Ltd (TEL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • OBJ Ltd (OBJ)-医療機器分野:企業M&A・提携分析
    Summary OBJ Ltd (OBJ) is a developer of magnetic micro-array drug and ingredient delivery technologies. The company offers services such as drug or ingredient profiling in skin, laboratory facilities and capabilities, formulation development, product development, product optimisation, and pre-commer …
  • Vallourec SA:企業の戦略・SWOT・財務情報
    Vallourec SA - Strategy, SWOT and Corporate Finance Report Summary Vallourec SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • China Gas Holdings Ltd (384):企業の財務・戦略的SWOT分析
    China Gas Holdings Ltd (384) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Sharps Compliance Corp (SMED):企業の財務・戦略的SWOT分析
    Summary Sharps Compliance Corp (Sharps) is a healthcare waste solution company that offers regulatory compliant services. The company offers products such as sharps disposal systems, public sharps safety, takeaway medication recovery system, collection and disposal system, complete needle collection …
  • Enel Green Power SpA:企業の戦略的SWOT分析
    Enel Green Power SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • NARI Technology Development Co Ltd (600406):企業の財務・戦略的SWOT分析
    NARI Technology Development Co Ltd (600406) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆